For the World Stroke Day this year, the World Stroke Organization has decided to dedicate it to the woman, Often she is the victim of this disease and needs thereby special attention. ARS Umbria has produced this short spot to help the public to know- understand and better prevent stroke in women. Directed by Marzia Raspa

The WHO atlas addresses the global epidemic of heart disease and stroke in a clear and accessible format.

Cardiovascular disease now ranks as the world s top causeof death, causing one third of all deaths globally. Heartdisease can no longer be seen as the problem ofoverworked, overweight middle-aged men in developed countries. In todays world, women and children too are atrisk. Already, 75% of all CVD deaths occur in the poorer regions of the world, and this is likely to increase in the future. Following on from the success of WHO s Tobacco Atlas , the Atlas of Heart Disease and Stroke  addresses this most
urgent health issue in a ground-breaking, clear and accessible format, designed to inform UN agencies,
government officials, politicians, and other decision makers, the media, researchers, and the general public, as well as provide an essential tool for the health professional.
IMG_1400
Topics include:

* Risk factors: high blood pressure, tobacco use,
inactivity, obesity, lipids, diabetes
* Women, childhood and youth
* The global burden of CVD, including the economic
burden
* Research
* Prevention
* Policies and legislation
* Treatment
* Predictions

IMG_1409

data from the ministery of health for central italy

So far it was a secret given to word of mouth among health professionals. The new Guide to Health Focus, now in its third edition with the most current data, it also recognizes the right of patients to know which are the most reliable centers to turn to be taken care of in the best way.Of course, hard to choose when you have a heart attack or a stroke: it relies on the ETS and it is hoped that in their region and in their local health healthcare is efficient.

“>1. Shall be established a biennial award for the best original scientific research conducted in the field “>youth
“>The honorary president of the award is Prof. Domenico Inzitari. “>author’s statement that the date of submission of the same work is not yet “acce “>2.
“>Italy, the Sin (Italian Society of Neurology), Sno (Neurological Hospital), the Region “>and the Order of Physicians of the Province of Vibo Valentia
“>3. Prizes will be awarded three jobs, with prizes “>euro, respectively, to be allocated
“>This year, the two scientific societies “>Neurological most representative (SIN and SNO) “>distributed “>the burden of premiums
“>4. The competition is open to researchers in experimental and clinical sciences in the field of stroke  “> in a clinical or research established in Italy. “>experimental design and conduct of research that has produced results “>such preferred securities.
brain. Must be research with scientific results and their originals. “>action
be paramount. “>articles, meta-analyzes or other items without
“>6. Entries must be sent in full (in Italian or English),
“>September 201 “>President of ‘Hipponion STROKE NATIONAL PRIZE, Dr. Domenico Consoli, Avenue of the
“>domco@tiscali.it
“>neurologiavv@live.it
“>sent by post, the date of dispatch of postmark) backed by sections
“>surfaces: table of contents, introduction, materials and methods, results, discussion,
words. “>, Under their own responsibility, the role he / she played in the research work. “>host / presenter, with regard to design, conduct of the study, analysis of results, year elements of privilege for the award. “>prepared an attached card that contains the data, the tax code, the professional role, the “>h and under its responsibility to “>7., The Commission will assess the scientific work sent anonymously each of three independent reviewers. “>tion will be:
“>Originality of the scientific question (innovative contribution compared to the previous knowledge of the
“>-
“>-
“>with the previous literature, score from 1 to 10.
“>Conclusions congruous with the results (degree of inference
“>generalizability of the results) pts “>to 10.
“>Overall assessment, taking into account the age of the investigator and the role he played in
“>In case of conflict between the two referees, the evaluation with
“>jointly by all the members of the advisory board.
“>directly by the candidate / in the premium, for the val
“>a report of 15 minutes (10 for presentation, 5 for discussion) to be held
“>No
“>and
“>9. Scientific work of the Committee will
“>10. The awards av
“>à
“>.
“>a
“>’Stroke’
. “>P. Binelli,
“>Carolei,
C. Fieschi, G.F. “>L. Provincial
“>Quattrone, V. Toso

IMG_1409

The European Stroke Organisation (ESO) announced on May 9th, 2014, that the first ESO Stroke Conference will be held in Glasgow on April 17-19, 2015. Here topics it will be nice to be there with all my colleagues. In the pipeline we have a couple of nice contributions

European Stroke Conference  #ESOC14 #eurostroke14 in Nice

#ESOC14 en còte d’azur

https://www.youtube.com/watch?v=YaQjM-SSohg

stroke guidelines

stroke guidelines

foto(14)

foto(15)

GUIDELINES for Stroke Management

The ESO Guidelines 2008 represent an update of the ESO 2008 and 2003 EUSI Guidelines. Again, they cover the whole spectrum of ischaemic stroke, from teaching and awareness, to stroke unit and stroke management strategies, primary and secondary prevention, acute treatment and rehabilitation.

The WordPress.com stats helper monkeys prepared a 2013 annual report for this blog.

Here’s an excerpt:

A San Francisco cable car holds 60 people. This blog was viewed about 910 times in 2013. If it were a cable car, it would take about 15 trips to carry that many people.

Click here to see the complete report.

Background

The SOCRATES study compares ticagrelor versus aspirin for the prevention of major vascular events in patients with acute ischemic stroke or transient ischemic attack [1,2].

Image

SOCRATES (Acute Stroke Or Transient IsChaemic Attack TReated with Aspirin or Ticagrelor and Patient OutcomES) is a global clinical trial involving 9,600 patients who have experienced an acute ischemic stroke or transient ischemic attack (TIA). Annually, 15 million people worldwide suffer a stroke of this type. Ischemic strokes occur as a result of an obstruction of a vessel supplying blood to the brain. A TIA is secondary to a temporary insufficient blood supply to parts of the brain and is often considered a warning sign that a stroke may follow.

SOCRATES is a randomized, parallel group study evaluating the efficacy of ticagrelor compared to aspirin in reducing major vascular events (composite of all-cause mortality, myocardial infarction [MI], and stroke) in patients with acute ischemic stroke (NIHSS ≤ 5) and TIA.

Also announced today is the initiation of THEMIS (Effect of Ticagrelor on Health Outcomes in DiabEtes Mellitus Patients Intervention Study), a global clinical trial involving 17,000 patients with Type 2 diabetes at high risk of cardiovascular (CV) events. Of the 340 million people who suffer from the disease, 90 percent have type 2 diabetes and 50 percent of whom die from CV disease.

“A major goal of treating patients with diabetes is to reduce their cardiovascular risk,” said THEMIS study co-chair Deepak L. Bhatt, MD, MPH, Professor of Medicine at Harvard Medical School and Senior Physician at Brigham and Women’s Hospital.

“THEMIS will allow us to test a bold new strategy in the care of patients with diabetes who are at high risk of myocardial infarction, stroke, and cardiovascular death,” stated THEMIS study co-chair Ph. Gabriel Steg, MD, Professor of Medicine at Université Paris-Diderot and Director of the Coronary Care Unit at Hôpital Bichat.

THEMIS is an event-driven, randomized, parallel group study evaluating the efficacy of long-term treatment with ticagrelor versus placebo for the prevention of major CV events – the composite of CV death, MI or stroke – in patients with Type 2 diabetes without a history of previous MI or stroke but with documented coronary atherosclerosis.

SOCRATES and THEMIS will be monitored by Independent Data Monitoring Committees who will review the safety and efficacy of treatments in these trials. The trials will be conducted in accordance with Good Clinical Practice. Both studies will be posted on clinicaltrials.gov in the near future.

AstraZeneca is currently collaborating with over 4,000 clinical investigators in more than 30 countries as part of the PARTHENON program, and has established partnerships with a number of pre-eminent research institutions. Other studies in the PARTHENON program include PEGASUS, studying BRILINTA for secondary prevention in patients with previous myocardial infarction, and EUCLID studying patients with Peripheral Artery Disease.

PARTHENON will provide an unparalleled dataset to build scientific understanding of BRILINTA in a broad a range of atherothrombotic conditions. AstraZeneca has approved more than 100 investigator sponsored studies, which will be starting during the coming year.

BRILINTA is currently not approved for the treatment of patients with ischemic stroke, TIA, peripheral artery disease, or for secondary prevention in patients with a history of previous myocardial infarction.

BRILINTA Indications

BRILINTA is indicated to reduce the rate of thrombotic cardiovascular (CV) events in patients with ACS (unstable angina [UA], non–ST-elevation myocardial infarction [NSTEMI], or ST-elevation myocardial infarction [STEMI]). In PLATO, BRILINTA has been shown to reduce the rate of a combined end point of CV death, myocardial infarction (MI), or stroke compared to clopidogrel. In PLATO, the difference between treatments was driven by CV death and MI with no difference in stroke. In patients treated with an artery-opening procedure known as percutaneous coronary intervention (PCI), BRILINTA reduces the rate of stent thrombosis.

BRILINTA has been studied in ACS in combination with aspirin. Maintenance doses of aspirin above 100 mg decreased the effectiveness of BRILINTA. Avoid maintenance doses of aspirin above 100 mg daily.

References

1.Giacalone G, Abbas MA, Corea F. Prevention strategies for cardioembolic stroke: present and future perspectives. Open Neurol J. 2010; 4:56-63. doi: 10.2174/1874205X01004020056.

2.Silvestrelli G, Corea F, Micheli S, Lanari A. Clinical pharmacology and vascular risk.Open Neurol J. 2010;4:64-72. doi: 10.2174/1874205X01004020064.

Follow

Get every new post delivered to your Inbox.

Join 208 other followers